SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 6.89 |
| Enterprise Value ($M) | 0.32 |
| Book Value ($M) | 6.19 |
| Book Value / Share | 0.39 |
| Price / Book | 1.11 |
| NCAV ($M) | 6.17 |
| NCAV / Share | 0.39 |
| Price / NCAV | 1.12 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.78 |
| Return on Assets (ROA) | -1.08 |
| Return on Equity (ROE) | -1.19 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.21 |
| Current Ratio | 8.21 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 7.03 |
| Assets | 7.05 |
| Liabilities | 0.86 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -7.63 |
| Net Income | -8.36 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -3.53 |
| Cash from Investing | -0.00 |
| Cash from Financing | 11.90 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Armistice Capital, Llc | 9.99 | ||
| 13G/A | Murphy John Raymond | 5.49 | 20.18 | |
| 13G | Pham Quang X | 48.57 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 29,422 | 104,471 | 28.16 | |
| 51,885 | 125,263 | 41.42 | |
| 32,887 | 111,704 | 29.44 | |
| 27,878 | 98,986 | 28.16 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CSBR – Champions Oncology, Inc. | CTXR – Citius Pharmaceuticals, Inc. |
| CUE – Cue Biopharma, Inc. | CYCC – Cyclacel Pharmaceuticals, Inc. |
| CYCN – Cyclerion Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io